Short answer
Arcutis Biotherapeutics, Inc. (ARQT) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $144M (up 45.1% year over year) with net income of $9M.
Q3 2026 key financials · XBRL
- Revenue
- $144M
- +45.1% YoY · +10.8% QoQ
- Net income
- $9M
- +18.8% YoY · −41.4% QoQ
- Operating margin
- 6.6%
- EPS (diluted)
- $0.06
- +0.0% YoY · −50.0% QoQ
Source: XBRL data from the Arcutis Biotherapeutics, Inc. (ARQT) Q3 2026 10-Q on SEC EDGAR. USD.
Arcutis Biotherapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly product revenue $143.9M, up $44.7M YoY from $99.2M
- Best performer: ZORYVE foam revenue $75.1M vs $49.8M YoY, up $25.4M
- ZORYVE cream 0.05% revenue $3.7M, launched October 2025
- Operating cash flow $33.8M in nine months vs $(31.8)M YoY, cash and securities $259.8M
- Outlook: R&D and SG&A expected to increase, primarily for ARQ-234 and ZORYVE commercialization
Risk Factors
- No material changes to risk factors disclosed in the December 31, 2025 Form 10-K
- Carried-forward risks include potential risks and uncertainties described in the 2025 Annual Report
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Arcutis Biotherapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.